BPTSY / Biophytis S.A. - Depositary Receipt (Common Stock) - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 3, 2025 Commission File Number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 3, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étag

Biophytis obtains EMA authorization to launch its Phase 2 clinical trial in obesity

Exhibit 99.1 Press release Biophytis obtains EMA authorization to launch its Phase 2 clinical trial in obesity Paris, France, Cambridge (Massachusetts, United States), September 3rd, 2025 – 7:00 a.m. CET – Biophytis SA ("the Company"), a pioneer in the development of transformative therapies for obesity, sarcopenia, and longevity, today announces that the European Medicines Agency (EMA) has issued

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 1, 2025 Commission File Number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 1, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étag

Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil

Exhibit 99.1 Press release Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil Paris, France, Cambridge (Massachusetts, United States), September 1st, 2025 – 7:00 a.m. CET – Biophytis SA ("the Company"), a pioneer in the development of transformative therapies for obesity, sarcopenia, and longevity, today provides a detailed update on its clinical and regulatory plan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: August 28, 2025 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: August 28, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage

Biophytis Receives EMA and Belgian Regulatory Approval to Initiate Phase 3 Sarcopenia Clinical Trial

Exhibit 99.1 Press release Biophytis Receives EMA and Belgian Regulatory Approval to Initiate Phase 3 Sarcopenia Clinical Trial Paris, France, Cambridge (Massachusetts, United States), August 28, 2025 – 7:00 a.m. CET – Biophytis SA ("the Company"), a pioneer in the development of transformative therapies for obesity, sarcopenia, and longevity, today announced that both Part I (European Medicines A

Biophytis Secures Non-Dilutive Bond Financing Line of up to €1 Million

Exhibit 99.1 Press release Biophytis Secures Non-Dilutive Bond Financing Line of up to €1 Million Paris, France, Cambridge (Massachusetts, United States), August 5, 2025 – 11:00 p.m. CET – Biophytis SA (“the Company”), a pioneer in the development of transformative therapies for obesity, sarcopenia, and longevity, announces the establishment of a non-dilutive bond financing line for a maximum amou

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: August 6th, 2025 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: August 6th, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 25, 2025 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 25, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 18, 2025 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 18, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 18, 2025 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 18, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis Wins Major Legal Victory Before the French Court of Cassation

Exhibit 99.1 Press release Biophytis Wins Major Legal Victory Before the French Court of Cassation Paris (France) and Cambridge (Massachusetts, USA), July 16, 2025 – 7:00 AM (CET) Biophytis SA, a pioneering force in the development of transformative therapies for obesity, sarcopenia, and longevity, announces a major legal victory. On July 9, 2025, the French Court of Cassation, the country’s highe

Biophytis Partners in AI with Lynx Analytics to Accelerate Drug Discovery for Sarcopenia

Exhibit 99.1 Press release Biophytis Partners in AI with Lynx Analytics to Accelerate Drug Discovery for Sarcopenia Paris (France) and Cambridge (Massachusetts, États-Unis), July 15, 2025 – 07:00am – Biophytis SA, a pioneering force in the development of transformative therapies for obesity, sarcopenia, and longevity, today announced a strategic partnership with Lynx Analytics, a pioneer in artifi

Biophytis at the Forefront of Longevity Innovation at the World Aging & Rejuvenation Conference 2025

EX-99.1 2 tm2521147d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Press release Biophytis at the Forefront of Longevity Innovation at the World Aging & Rejuvenation Conference 2025 Paris (France) and Cambridge (Massachusetts, USA), July 8, 2025 – 7:00 AM (CET) Biophytis SA, a pioneering force in the development of transformative therapies for obesity, sarcopenia, and longevity, today announces its partici

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 17, 2025 Commission File Number: 001-38

6-K 1 tm2521147d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 17, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne Universi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 11, 2025 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 11, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis Reports 2024 Financial Results and 2025 Outlook

Exhibit 99.1 Press release Biophytis Reports 2024 Financial Results and 2025 Outlook · Plans to initiate Phase 2 study in obesity and Phase 3 study in sarcopenia as soon as possible. · Continued partnership strategy to support the funding of clinical programs. · Strengthening of the drug discovery platform through the integration of disruptive technologies. Paris (France) and Cambridge (Massachuse

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 9, 2025 Commission File Number: 001-389

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 9, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4 p

Biophytis Powers Innovation in Obesity, Muscle Health, and Longevity at BIO International 2025

Exhibit 99.1 Press release Biophytis Powers Innovation in Obesity, Muscle Health, and Longevity at BIO International 2025 Paris, France, Cambridge (Massachusetts, USA), July 3, 2025 – 07h00 — Biophytis, a pioneering force in the development of transformative therapies for obesity, sarcopenia, and longevity, is proud to announce its successful participation at the BIO International Convention 2025,

Information on the Annual Financial Statements

Exhibit 99.1 Press release Information on the Annual Financial Statements Paris (France) and Cambridge (Massachusetts, USA), June 30, 2025 – 10:30 PM (CET) – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in developing treatments for age-related diseases announces that it is not in a position to publish its 2024 annu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 3, 2025 Commission File Number: 001-389

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 3, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4 p

Biophytis announces the temporary suspension of the trading of its shares

Exhibit 99.1 Communiqué de presse Biophytis announces the temporary suspension of the trading of its shares Paris (France) and Cambridge (Massachusetts, USA), June 19, 2025 – 11:00 PM (CET) – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in developing treatments for age-related diseases announces the temporary suspe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 24, 2025 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 24, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis announces its participation in the BIO International Convention from June 16 to 19

Exhibit 99.1 Press release Biophytis announces its participation in the BIO International Convention from June 16 to 19 Paris, France, Cambridge (Massachusetts, USA), 04th June 2025 – 7:00 AM – Biophytis SA (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today announces its

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 4, 2025 Commission File Number: 001-389

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 4, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4 p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 2, 2025 Commission File Number: 001-389

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 2, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4 p

Information on the Annual Financial Statements

Exhibit 99.1 Press release Information on the Annual Financial Statements Paris (France) and Cambridge (Massachusetts, USA), May 30, 2025 – 04:00 PM (CET) – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in developing treatments for age-related diseases announces that, due to exceptional circumstances related to tech

Biophytis Highlights Innovative Approach to Obesity Treatment During Key ECO 2025 Presentation

Exhibit 99.1 Press release Biophytis Highlights Innovative Approach to Obesity Treatment During Key ECO 2025 Presentation Paris (France) and Cambridge (Massachusetts, USA), May 15, 2025 - 07:00 AM (CET) - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specializing in developing treatments for age-related diseases, today announced its active participation at the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 15, 2025 Commission File Number: 001-389

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 15, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4 p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ¨ Form 10-K x Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2024 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

Postponement of the publication of the annual financial statements

Exhibit 99.1 Press release Postponement of the publication of the annual financial statements Paris (France) and Cambridge (Massachusetts, USA), April 25, 2025 – 7:00 AM (CET) – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in developing treatments for age-related diseases, announces the postponement of the publicat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 29, 2025 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 29, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 22, 2025 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 22, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis targets mobility restoration in patients with obesity

Exhibit 99.1 Press release Biophytis targets mobility restoration in patients with obesity Paris (France) and Cambridge (Massachusetts, USA), April 22, 2025 – 7:00 AM (CET) – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in developing treatments for age-related diseases strentghens its position as one of the leading

Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity

Exhibit 99.1 Press release Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity Paris, France, Cambridge (Massachusetts, États-Unis), 8th april 2025 – 07:00am – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, confirms the launch of the Ph

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 9, 2025 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 9, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 31, 2025 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 31, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis announces the settlement and delivery of its €2.6 million private placement

Exhibit 99.1 Press release Biophytis announces the settlement and delivery of its €2.6 million private placement NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA Paris (France) and Cambridge (Massachusetts, USA), March 28, 2025 – 10:00 PM (CET) – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a cl

SUBSCRIPTION AGREEMENT in the context of a capital increase of BIOPHYTIS S.A.

Exhibit 10.1 THIS PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT (THE “AGREEMENT”) RELATES TO AN OFFERING OF SECURITIES RELYING UPON ONE OR MORE EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE FEDERAL SECURITIES LAWS OF THE UNITED STATES OF AMERICA. NONE OF THE SECURITIES TO WHICH THIS SUBSCRIPTION AGREEMENT RELATES HAVE BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURI

Biophytis announces the successful completion of a €2,6 million private placement

Exhibit 99.1 Press release Biophytis announces the successful completion of a €2,6 million private placement § Capital increase of a total amount of approximately €2,6 million in gross proceeds by issuing 4,307,614 new shares, each with one share warrant attached, at €0,26 per unit, and 5,692,308 pre-funded warrants, each with one share warrant attached, at €0,25 per pre-funded unit; § Gross proce

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 26, 2025 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 26, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 20, 2025 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 20, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China

Exhibit 99.1 Press release Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China Paris, France, Cambridge (Massachusetts, USA), 21 january 2025 – 7:00 AM – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today announces

Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101

Exhibit 99.1 Press release Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101 Paris (France) and Cambridge (Massachusetts, USA), 14 January 2025 – 7:00 AM – Biophytis SA (Euronext Growth Paris: ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 14, 2025 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 14, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage

* * * *

Exhibit 99.1 Press release Biophytis Announces New Cash Contribution and Debt Conversion up to €8.6 million to Finance the Obesity Program · Cash contribution of €2.5 million from existing and new investors to finance the clinical development of BIO101 in obesity · Conversion into equity of debt for up to €6.1 million strengthening the balance sheet Paris, France and Cambridge (Massachusetts, USA)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 8, 2025 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 8, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University-BC 9, Bâtiment A 4ème étage

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 6, 2025 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 6, 2025 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University-BC 9, Bâtiment A 4ème étage

Biophytis announces temporary suspension of the listing of its shares and share warrants prior to the completion of a refinancing transaction

Exhibit 99.1 Press release Biophytis announces temporary suspension of the listing of its shares and share warrants prior to the completion of a refinancing transaction Paris, France and Cambridge (Massachusetts, USA), 6 January, 2025 – 8:30 AM (CET) – Biophytis SA (Euronext Growth Paris: ALBPS; OTC Markets: BPTSY), a clinical-stage biotechnology company specializing in developing treatments for a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 30, 2024 Commission File Number: 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 30, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University-BC 9, Bâtiment A 4ème éta

French Public Limited Company with a Board of Directors and a share-capital of €5,235,953.60 Registered office: 14 Avenue de l'Opéra - 75001 PARIS RCS PARIS 492 002 225 INTERIM FINANCIAL REPORT AS OF JUNE 30, 2024

Exhibit 99.1 French Public Limited Company with a Board of Directors and a share-capital of €5,235,953.60 Registered office: 14 Avenue de l'Opéra - 75001 PARIS RCS PARIS 492 002 225 INTERIM FINANCIAL REPORT AS OF JUNE 30, 2024 Interim financial report as of June 30, 2024 CONTENTS 1. Declaration by the person responsible for the interim financial report 5 1.1 Person responsible for the interim fina

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 22, 2024 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 22, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia

Exhibit 99.1 Press release Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia Paris, France, Cambridge (Massachusetts, USA), 22 July 2024 – 7:00 AM – Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today announces the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 11, 2024 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 11, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity

Exhibit 99.1 Press release Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity Paris (France) and Cambridge (Massachusetts, USA), July 11, 2024 – 07:00am CET – Biophytis SA (Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announced

Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris

Exhibit 99.1 Press release Biophytis presented its Phase 2-3 COVA study results in severe forms of Covid-19 at the WCID in Paris Paris (France) and Cambridge (Massachusetts, USA), July 01st, 2024 – 07:00am CET – Biophytis SA (Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 1, 2024 Commission File Number: 001-389

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 1, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4 p

RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024 All resolutions presented by the Company have been adopted

Exhibit 99.1 Press release RESULTS OF THE COMBINED GENERAL MEETING ON JUNE 24, 2024 All resolutions presented by the Company have been adopted Paris (France) and Cambridge (Massachusetts, USA), June 25, 2024 – 11:00pm CET – Biophytis SA (Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-rela

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 26, 2024 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 26, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million

Exhibit 99.1 Press release Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up to €108 Million · Biophytis to receive upfront and milestones payments for a total amount up to €108 million, as well as double-digit royalties on future sales of the product · Agreement covers commercialization of BIO101 in Latin America · Biophytis and Blanver intend to collaborat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 20, 2024 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 20, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis extends its contract with Atlas to secure financing for its business activities

Exhibit 99.1 Press release Biophytis extends its contract with Atlas to secure financing for its business activities Important note: Biophytis has set up financing in the form of Bonds redeemable in cash and in new and existing shares (ORNANE) with the company Atlas, which, after having received the shares resulting from the conversion or exercise of these instruments, is not intended to remain a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 20, 2024 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 20, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens

Exhibit 99.1 Press release Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens Paris (France) and Cambridge (Massachusetts, USA), June 12, 2024 – 07:00 am CET – Biophytis SA (Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 14, 2024 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 14, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 11, 2024 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 11, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity

Exhibit 99.1 Press release Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity Paris (France) and Cambridge (Massachusetts, USA), June 10, 2024 – 07:00 am CET – Biophytis SA (Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, tod

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 7, 2024 Commission File Number: 001-389

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 7, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4 p

Combined General Meeting of June 24, 2024

Exhibit 99.1 Press release Combined General Meeting of June 24, 2024 Paris (France) and Cambridge (Massachusetts, USA), June 7, 2024 – 07:30 am CET – Biophytis SA (Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, will hold its Combined General Meeting (CGM) on June 24, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 14, 2024 Commission File Number: 001-389

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 14, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4 p

Biophytis announces the design of its phase 2 OBA clinical study in obesity

Exhibit 99.1 Press release Biophytis announces the design of its phase 2 OBA clinical study in obesity Paris (France) and Cambridge (Massachusetts, USA), May 14, 2024 – 07:00 am CET – Biophytis SA (Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces the design

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 29, 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 29, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis is deploying its partnership strategy in obesity

Exhibit 99.1 Press release Biophytis is deploying its partnership strategy in obesity Paris (France) and Cambridge (Massachusetts, USA), April 29, 2024 – 07:00 am CET – Biophytis SA (Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces the implementation of a d

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 25, 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 25, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis Announces Transfer of ADSs to OTC Market

Exhibit 99.1 Press release Biophytis Announces Transfer of ADSs to OTC Market · ADSs delisted from Nasdaq, which will result in meaningful savings · ADSs transferred to OTC Pink market; Company will apply to trade on OTCQB market · Biophytis remains listed on Euronext Growth Paris as its primary trading market Paris (France) and Cambridge (Massachusetts, USA), April 24, 2024 – 11:00pm CET – Biophy

Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program

Exhibit 99.1 Press release Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program Paris (France) and Cambridge (Massachusetts, USA), April 19, 2024 – 07:00am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseas

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 19, 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 19, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity IND to be filed with the FDA in the coming weeks

Exhibit 99.1 Press release Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity IND to be filed with the FDA in the coming weeks Paris (France) and Cambridge (Massachusetts, USA), April 18, 2024 – 07:00am CET – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 18, 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 18, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 15, 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 15, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis files a patent application and strengthens its intellectual property in obesity

Exhibit 99.1 Press release Biophytis files a patent application and strengthens its intellectual property in obesity Paris (France) and Cambridge (Massachusetts, USA), April 15, 2024 – 07:00am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related dis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 9, 2024 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 9, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis announces its 2023 financial results and provides an update on its business activities

Exhibit 99.1 Press release Biophytis announces its 2023 financial results and provides an update on its business activities Paris (France) and Cambridge (Massachusetts, USA), April 08, 2024 – 11:00pm CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-rela

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 9, 2024 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 9, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024

Exhibit 99.1 Press release Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024 Paris (France) and Cambridge (Massachusetts, USA), April 08, 2024 – 11:00pm CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "

Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Nicolas Fellmann, certify that: 1. I have reviewed this annual report on Form 20-F of BIOPHYTIS S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or

Consent of Independent Registered Public Accounting Firm

Exhibit 15.2 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1) Registration Statement (Form F-1 No. 333-273718) of Biophytis SA, and (2) Registration Statement (Form F-3 No. 333-271385) of Biophytis SA; of our report dated April 21, 2022, except for Note 13.2.3, as to which the date is January 30, 202

Recovery policy under the SEC’s compensation clawback rules

Exhibit 97.1 Recovery policy under the SEC’s compensation clawback rules Objective To recover erroneously awarded incentive-based compensation during a recovery period when the accounting restatement changes financial reporting measures that affect the amount of such compensation. Effective date : December 1, 2023 The policy applies only to incentive-based compensation received on or after the eff

Consent of Independent Registered Public Accounting Firm

Exhibit 15.1 KPMG S.A. Tour EQHO 2 Avenue Gambetta CS 60055 92066 Paris la Défense Cedex France Téléphone : Télécopie : Site internet : +33 (0)1 55 68 68 68 +33 (0)1 55 68 73 00 www.kpmg.fr Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the registration statement No. 333-273718 on Form F-1 and the registration statement No. 333-271385 on Fo

Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of BIOPHYTIS S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stanislas Veil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of BIOPHYTIS S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nicolas Fellma

Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Stanislas Veillet, certify that: 1. I have reviewed this annual report on Form 20-F of BIOPHYTIS S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024 All resolutions presented by the Company have been adopted

Exhibit 99.1 Press release RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024 All resolutions presented by the Company have been adopted Paris (France) and Cambridge (Massachusetts, USA), April 04, 2024 – 11:0pm CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 5, 2024 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 5, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis presented its phase 3 protocol in the treatment of sarcopenia

Exhibit 99.1 Press release Biophytis presented its phase 3 protocol in the treatment of sarcopenia Paris (France) and Cambridge (Massachusetts, USA), March 22, 2024 – 07:00am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degener

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 22, 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 22, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis announces the implementation of a reverse stock split of its ordinary shares

Exhibit 99.1 Press release Biophytis announces the implementation of a reverse stock split of its ordinary shares Paris (France) and Cambridge (Massachusetts, USA), March 15, 2024 – 11pm CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 18, 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 18, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Combined General Meeting of April 2, 2024

Exhibit 99.1 Press release Combined General Meeting of April 2, 2024 Paris (France) and Cambridge (Massachusetts, USA), March 18, 2024 – 7:00 A.M. CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 18, 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 18, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 12, 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 12, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis announces its participation in several events in Europe and the United States over the coming months

Exhibit 99.1 Press release Biophytis announces its participation in several events in Europe and the United States over the coming months Paris (France) and Cambridge (Massachusetts, USA), March 12, 2024 – 07:00am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutic

Biophytis presented the potential of RuvembriTM in the treatment of Duchenne Muscular Dystrophy

Exhibit 99.1 Press release Biophytis presented the potential of RuvembriTM in the treatment of Duchenne Muscular Dystrophy Paris (France) and Cambridge (Massachusetts, USA), March 8, 2024 – 07:00am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 8, 2024 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 8, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 22, 2024 Commission File Number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 22, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étag

"Healthy aging" Publication of a book on the medicine and science of longevity

Exhibit 99.1 Press release "Healthy aging" Publication of a book on the medicine and science of longevity Paris (France) and Cambridge (Massachusetts, USA), February 22, 2024 – 07:00am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 5, 2024 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 5, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 5, 2024 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 5, 2024 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage

Biophytis announces the drawing of the fourth tranche of ORNANE under the 2021 Atlas Contract

Exhibit 99.1 Press release Biophytis announces the drawing of the fourth tranche of ORNANE under the 2021 Atlas Contract Paris (France) and Cambridge (Massachusetts, USA), December 29, 2023 – 07:00am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the

Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet

Exhibit 99.1 Press release Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet Paris (France) and Cambridge (Massachusetts, USA), January 4th ,2023 – 07:00am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the development of therapeutics tha

Biophytis announces its participation in several conferences in Europe and the US during the first quarter of 2024

Exhibit 99.1 Press release Biophytis announces its participation in several conferences in Europe and the US during the first quarter of 2024 Paris (France) and Cambridge (Massachusetts, USA), December 11, 2023 – 07am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: December 11, 2023 Commission File Number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: December 11, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étag

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: December 5, 2023 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: December 5, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage

Biophytis and the University of Liège explore the potential of Sarconeos (BIO101) in the treatment of viral respiratory failure

Exhibit 99.1 Press release Biophytis and the University of Liège explore the potential of Sarconeos (BIO101) in the treatment of viral respiratory failure Paris (France) and Cambridge (Massachusetts, USA), December 4, 2023 – 07:00am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the development of therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 28, 2023 Commission File Number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 28, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étag

Biophytis appoints Yann Meunier and Bernard Lévy to its Scientific Advisory Board

Exhibit 99.1 Press release Biophytis appoints Yann Meunier and Bernard Lévy to its Scientific Advisory Board Paris (France) and Cambridge (Massachusetts, USA), November 27, 2023 – 7am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing th

Biophytis announces the success of its capital increase with preferential subscription rights for approximately €1.96 million

Exhibit 99.1 Press release Biophytis announces the success of its capital increase with preferential subscription rights for approximately €1.96 million Paris (France) and Cambridge (Massachusetts, United States), November 20, 2023 – 07:00am – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the developm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 21, 2023 Commission File Number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 21, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étag

Biophytis announces receipt of Nasdaq Notice

Exhibit 99.1 Press release Biophytis announces receipt of Nasdaq Notice Paris (France) and Cambridge (Massachusetts, USA), November 17, 2023 – 11pm CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 21, 2023 Commission File Number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 21, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étag

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 7, 2023 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 7, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage

Biophytis to attend BIO-Europe in Munich

Exhibit 99.1 Press release Biophytis to attend BIO-Europe in Munich Paris (France) and Cambridge (Massachusetts, USA), November 06, 2023 – 07:00 am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated

Biophytis and Innovation Solutions Pharma sign a partnership agreement to accelerate market access for Sarconeos (BIO101) in Brazil

Exhibit 99.1 Press Release Biophytis and Innovation Solutions Pharma sign a partnership agreement to accelerate market access for Sarconeos (BIO101) in Brazil Paris (France) and Cambridge (Massachusetts, USA), October 30 ,2023 – 06:00 – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the development of therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 2, 2023 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 2, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage

Biophytis receives notice of delisting from Nasdaq and announces it will request a hearing before the Nasdaq Hearings Panel

Exhibit 99.1 Press Release Biophytis receives notice of delisting from Nasdaq and announces it will request a hearing before the Nasdaq Hearings Panel Paris (France) and Cambridge (Massachusetts, USA), October 26 ,2023 – 11:00pm CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the development of therapeutics

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: October 26, 2023 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: October 26, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage

Biophytis announces the launch of a rights issue with maintenance of shareholders’ preferential subscription rights to continue the execution of its strategic roadmap

Exhibit 99.1 Press release Biophytis announces the launch of a rights issue with maintenance of shareholders’ preferential subscription rights to continue the execution of its strategic roadmap § Public offering of ABSARs: new shares with redeemable share subscription warrants (BSARs) § Subscription price: €0.0093 per new share each with a subscription warrant § Subscription ratio: 3 ABSARs for 8

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: October 23, 2023 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: October 23, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: October 23, 2023 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: October 23, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 28, 2023 Commission File Number: 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 28, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème éta

Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)

Exhibit 99.1 Press Release Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101) Paris (France) and Cambridge (Massachusetts, USA), September 25, 2023 – 07:00 am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing

French public limited company with a Board of Directors with share capital of €4,267,706.99 Registered office: 14 Avenue de l'Opéra – 75001 PARIS Paris Commercial Register (RCS) 492 002 225 HALF-YEAR FINANCIAL REPORT AS OF JUNE 30, 2023

Exhibit 99.1 French public limited company with a Board of Directors with share capital of €4,267,706.99 Registered office: 14 Avenue de l'Opéra – 75001 PARIS Paris Commercial Register (RCS) 492 002 225 HALF-YEAR FINANCIAL REPORT AS OF JUNE 30, 2023 Half-year financial report as of June 30, 2023 CONTENTS 1. Activity report as of June 30, 2023 4 1.1 Business trends and significant events 4 1.2 Anal

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 27, 2023 Commission File Number: 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 27, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University-BC 9, Bâtiment A 4ème éta

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 20, 2023 Commission File Number: 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 20, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème éta

Biophytis provides an update on its early access programs for Sarconeos (BIO101) in the treatment of severe forms of COVID-19

Exhibit 99.1 Press release Biophytis provides an update on its early access programs for Sarconeos (BIO101) in the treatment of severe forms of COVID-19 Paris (France) and Cambridge (Massachusetts, USA), September 19, 2023 – 07:00 am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the development of therapeu

Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer

Exhibit 99.1 Press release Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer Paris (France) and Cambridge (Massachusetts, USA), September 14, 2023 – 07:00 am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 14, 2023 Commission File Number: 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 14, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème éta

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 11, 2023 Commission File Number: 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 11, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème éta

Biophytis obtains FDA Authorization to initiate the SARA-31 phase 3 study in sarcopenia

Exhibit 99.1 Press release Biophytis obtains FDA Authorization to initiate the SARA-31 phase 3 study in sarcopenia Paris (France) and Cambridge (Massachusetts, USA), September 11, 2023 – 07:00 am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the deg

Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York

Exhibit 99.1 Press release Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York Paris (France) and Cambridge (Massachusetts, USA), September 4, 2023 – 11:00 pm CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are ai

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 5, 2023 Commission File Number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 5, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étag

Biophytis announces next regulatory steps in Europe and the United States for its COVA project

Exhibit 99.1 Press release Biophytis announces next regulatory steps in Europe and the United States for its COVA project Paris (France) and Cambridge (Massachusetts, USA), August 16, 2023 – 07:00 am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the

Biophytis receives a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe

Exhibit 99.1 Press release Biophytis receives a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe Paris (France) and Cambridge (Massachusetts, USA), August 8, 2023 – 07:00 am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the deg

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: August 25, 2023 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: August 25, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: August 25, 2023 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: August 25, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage

As filed with the Securities and Exchange Commission on August 4, 2023

As filed with the Securities and Exchange Commission on August 4, 2023 Registration No.

Calculation of Filing Fee Tables Form F-1 (Form Type) Biophytis S.A. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) Biophytis S.A. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Ordinary shares,

BIOPHYTIS Public limited company with Board of Directors and capital of 5.371.786,64 Euros Registered office: 14 avenue de l’Opéra - 75001 Paris 492 002 225 RCS Trade and Company Register of Paris

Exhibit 3.1 Translation for information purposes only BIOPHYTIS Public limited company with Board of Directors and capital of 5.371.786,64 Euros Registered office: 14 avenue de l’Opéra - 75001 Paris 492 002 225 RCS Trade and Company Register of Paris ARTICLES OF ASSOCIATION Updated by the decision of the Chief Executive Officer dated 24 July 2023 Certified by the Chairman and Chief Executive Offic

Biophytis Announces $3.8 Million Registered Direct Offering

Exhibit 99.1 Press release Biophytis Announces $3.8 Million Registered Direct Offering Paris (France) and Cambridge (Massachusetts, USA), July 19, 2023 – 07:45am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 21, 2023 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 21, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

PLACEMENT AGENCY AGREEMENT July 18, 2023

Exhibit 10.2 PLACEMENT AGENCY AGREEMENT July 18, 2023 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), Biophytis S.A., a société anonyme organized under the laws of France and registered with the Register of Commerce and Companies (Registre du Commerce et des Sociétés) of Paris und

Terms and Conditions of the Warrants

Exhibit 10.3 Terms and Conditions of the Warrants THESE TERMS AND CONDITIONS OF THE WARRANTS DO NOT CONSTITUTE A CERTIFICATE REPRESENTING THE PRE-FUNDED WARRANTS. TERMS AND CONDITIONS OF THE PRE-FUNDED WARRANTS Biophytis S.A., a société anonyme organized under the laws of France and registered with the Register of Commerce and Companies (Registre du Commerce et des Sociétés) of Paris under the num

FORM OF INVESTOR SUBSCRIPTION AGREEMENT

Exhibit 10.1 FORM OF INVESTOR SUBSCRIPTION AGREEMENT Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4 pace Jussieu 75005 Paris, France The undersigned (the “Investor”) hereby confirms its agreement with you as follows: 1. This Subscription Agreement (the “Agreement”) is made as of the date set forth below between Biophytis S.A., a societé anonyme organized under the laws of France,

TERMS AND CONDITIONS OF THE WARRANTS

Exhibit 10.4 NEITHER THE WARRANTS NOR THE WARRANT SHARES INTO WHICH THESE WARRANTS ARE EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, UNTIL THE WARRANTS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 20, 2023 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 20, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

EX-FILING FEES

Exhibit 107 The prospectus supplement to which this Exhibit is attached is a final prospectus for the related offering of equity securities. The maximum aggregate offering price of the offering is $3,800,002.

Biophytis has requested a pre-submission meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the treatment of COVID-19

Exhibit 99.1 Press release Biophytis has requested a pre-submission meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the treatment of COVID-19 Paris (France) and Cambridge (Massachusetts, USA), July 20, 2023 – 07:00am CET – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris : ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the develop

50,500,000 Ordinary Shares Represented by 505,000 American Depositary Shares Pre-Funded Warrants to Purchase up to 82,833,400 Ordinary Shares Represented by 828,334 American Depositary Shares Up to 82,833,400 Ordinary Shares Represented by 828,334 Am

PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (To Prospectus dated May 1, 2023) Registration No.

Biophytis Announces $3.8 Million Registered Direct Offering

Exhibit 99.1 Press release Biophytis Announces $3.8 Million Registered Direct Offering Paris (France) and Cambridge (Massachusetts, USA), July 19, 2023 – 07:45am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 19, 2023 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 19, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 18, 2023 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 18, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis and SEQENS sign a partnership to produce Sarconeos (BIO101) active compound

Exhibit 99.1 Press release Biophytis and SEQENS sign a partnership to produce Sarconeos (BIO101) active compound Paris, France, 18 July 2023 – 7:00am CET – Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), («Biophytis»), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and impr

Biophytis has filed with the FDA for authorization to initiate SARA-31 phase 3 study in sarcopenia

Exhibit 99.1 Press release Biophytis has filed with the FDA for authorization to initiate SARA-31 phase 3 study in sarcopenia Paris (France) and Cambridge (Massachusetts, U.S.), July 10, 2023 – 07:00am CET - Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company specializing in the development of therapies aimed at slowin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 10, 2023 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 10, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with Amendment No. 1 to the Annual Report of BIOPHYTIS S.A. (the “Company”) on Form 20-F/A for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A (Amendment No. 1)

true UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A (Amendment No. 1) (Mark One) ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15

Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Nicolas Fellman, certify that: 1. I have reviewed this Amendment No. 1 to the annual report on Form 20-F/A of BIOPHYTIS S.A.; 2. Based on my knowledge, this report does not contain any untrue statemen

Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Stanislas Veillet, certify that: 1. I have reviewed this Amendment No. 1 to the annual report on Form 20-F/A of BIOPHYTIS S.A.; 2. Based on my knowledge, this report does not contain any untrue statem

Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with Amendment No. 1 to the Annual Report of BIOPHYTIS S.A. (the “Company”) on Form 20-F/A for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report

RESULTS OF THE ANNUAL GENERAL MEETING ON JUNE 16, 2023 ALL RESOLUTIONS PRESENTED BY THE COMPANY HAVE BEEN ADOPTED

Exhibit 99.1 Press release RESULTS OF THE ANNUAL GENERAL MEETING ON JUNE 16, 2023 ALL RESOLUTIONS PRESENTED BY THE COMPANY HAVE BEEN ADOPTED Paris, France and Cambridge (Massachusetts, USA), June 16, 2023 – 11pm CET - Biophytis SA (Nasdaq CM : BPTS, Euronext Growth Paris : ALBPS), («Biophytis» or the «company»), a clinical-stage biotechnology company focused on the development of therapeutics that

Biophytis reports clinical results for Sarconeos (BIO101) in sarcopenia treatment at the 16th SCWD International Congress

Exhibit 99.1 Press release Biophytis reports clinical results for Sarconeos (BIO101) in sarcopenia treatment at the 16th SCWD International Congress Paris (France) and Cambridge (Massachusetts, USA), June 19, 2023 – 07am CET - Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), («Biophytis» or the «company»), a clinical-stage biotechnology company focused on the development of therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 20, 2023 Commission File Number: 001-38

6-K 1 tm2317799d26k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 20, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne Universi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 20, 2023 Commission File Number: 001-38

6-K 1 tm2317799d36k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 20, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne Universi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 5, 2023 Commission File Number: 001-389

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: June 5, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4 p

Biophytis to participate at the BIO International Convention in Boston from the 5th to the 8th of June

Exhibit 99.1 Press release Biophytis to participate at the BIO International Convention in Boston from the 5th to the 8th of June Paris (France), Cambridge (Massachusetts, United States), June 5th, 2023 – 8am CET - Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics that slow

Biophytis has filed with the French National Authority for Health (HAS) an application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the treatment of severe forms of COVID-19

Exhibit 99.1 Press release Biophytis has filed with the French National Authority for Health (HAS) an application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the treatment of severe forms of COVID-19 Paris (France), Cambridge (Massachusetts, U.S.), March 26, 2023, 8am CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-sta

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 26, 2023 Commission File Number: 001-389

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 26, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4 p

Biophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference

Exhibit 99.1 Press release Biophytis Presented Positive Results of Phase 2-3 COVA Study At The American Thoracic Society International Conference Paris (France), Cambridge (Massachusetts, U.S.), May 25th, 2023, 08 am CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused on the development of therapeutics tha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 25, 2023 Commission File Number: 001-389

6-K 1 tm2316998d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 25, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne Universit

Biophytis has filed with the EMA for authorization to initiate SARA-31 phase 3 study in sarcopenia

Exhibit 99.1 Press release Biophytis has filed with the EMA for authorization to initiate SARA-31 phase 3 study in sarcopenia Paris (France), Cambridge (Massachusetts, U.S.), May 15, 2023, 08:00 CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerativ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 15, 2023 Commission File Number: 001-389

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 15, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4 p

Successful capital increase for Biophytis with €2.3 million raised

Exhibit 99.1 Press release Successful capital increase for Biophytis with €2.3 million raised · Success of the placement with professional investors, historical supporters of the Company, for an amount of €1.9M. · Strong participation of retail investors via the PrimaryBid platform with an offer allocated to €0.4M1. · Funds raised to finance the Marketing Authorisation Applications of Sarconeos (B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 11, 2023 Commission File Number: 001-389

6-K 1 tm2315507d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 11, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne Universit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 9, 2023 Commission File Number: 001-3897

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 9, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4 pl

Biophytis has requested a pre-submission meeting with the EMA for the Marketing Authorisation of Sarconeos (BIO101) for the treatment of COVID-19

Exhibit 99.1 Press release Biophytis has requested a pre-submission meeting with the EMA for the Marketing Authorisation of Sarconeos (BIO101) for the treatment of COVID-19 Paris (France), Cambridge (Massachusetts, U.S.), May 9th, 2023, 08:00 CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused on the devel

Biophytis strengthens its management team

Exhibit 99.1 Press release Biophytis strengthens its management team · Appointment of Chiara Baccelli as Director of Pharmaceutical Operations and Quality Assurance · Appointment of Nicolas Fellmann as Chief Financial Officer Paris (France), Cambridge (Massachusetts, United States) May 2, 2023 – 08:00 AM CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis

Biophytis announces receipt of Nasdaq Notice

Exhibit 99.1 Press release Biophytis announces receipt of Nasdaq Notice Paris (France), Cambridge (Massachusetts, U.S.), April 28th, 2023, 23:00 CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including sever

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 2, 2023 Commission File Number: 001-3897

6-K 1 tm2314380d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 2, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 2, 2023 Commission File Number: 001-3897

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: May 2, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4 pl

BIOPHYTIS S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4 place Jussieu 75005 Paris, France +33 1 44 27 23 00

BIOPHYTIS S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4 place Jussieu 75005 Paris, France +33 1 44 27 23 00 April 27, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, D.C. 20549 Attention: Sean Healy Re: Biophytis S.A. (the “Registrant”) - Request for Acceleration Registration Statement on Form F-3 File No. 333- 271

As filed with the Securities and Exchange Commission on April 21, 2023

As filed with the Securities and Exchange Commission on April 21, 2023 Registration No.

Form of Indenture (including form of debt securities)

Exhibit 4.6 BIOPHYTIS S.A. and [ ], as Trustee FORM OF INDENTURE Dated as of , Table of Contents Page Article 1 Definitions SECTION 1.01. Certain Terms Defined 1 Article 2 Securities SECTION 2.01. Forms Generally 4 SECTION 2.02. Form of Trustee’s Certification of Authentication 4 SECTION 2.03. Amount Unlimited; Issuable in Series 4 SECTION 2.04. Authentication and Delivery of Securities 6 SECTION

CALCULATION OF FILING FEE TABLES Form F-3 (Form Type) Biophytis S.A. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

EX-FILING FEES 7 tm2313194d1ex-filingfees.htm EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLES Form F-3 (Form Type) Biophytis S.A. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price F

Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of BIOPHYTIS S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Philippe Rouss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF

Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of BIOPHYTIS S.A. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stanislas Veil

Ernst & Young Et Autres Audit’s letter, dated April 18, 2023

Exhibit 15.1 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read Item 16F. Change in Registrant’s Certifying Accountant on pages 191 to 193 of Form 20-F dated April 17, 2023, of Biophytis S.A. and are in agreement with the statements contained in paragraphs one, four, and six. Regarding the registrant's statement concerning the lack of inte

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 19, 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 19, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Philippe Rousseau, certify that: 1. I have reviewed this annual report on Form 20-F of BIOPHYTIS S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or

Biophytis regains compliance with NASDAQ minimum bid price requirement

Exhibit 99.1 Press release Biophytis regains compliance with NASDAQ minimum bid price requirement Paris (France), Cambridge (Massachusetts, U.S.), April 19, 2023, 8am CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with

Certificate of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Stanislas Veillet, certify that: 1. I have reviewed this annual report on Form 20-F of BIOPHYTIS S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or

Biophytis Announces 2022 Financial Results and 2023 Perspectives

Exhibit 99.1 Press release Biophytis Announces 2022 Financial Results and 2023 Perspectives ü €11.1M of available cash and equivalents on December 31, 2022, and financing instruments for a total of €22M allowing financial visibility beyond mid 2024 ü Positive results of the Phase 2-3 COVA study for the treatment of severe COVID-19 with Sarconeos (BIO101) ü Early Access Program (EAP) submission in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 18, 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: April 18, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

The Combined General Meeting will be held on second call on April 17, 2023

Exhibit 99.1 Press release The Combined General Meeting will be held on second call on April 17, 2023 Paris (France), Cambridge (Massachusetts, U.S.), March 30th, 2023, 11 Pm CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 31, 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 31, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 27, 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 27, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis presented Sarconeos (BIO101) as a possible treatment candidate for long COVID after hospitalization during the 13th annual International Conference on Frailty and Sarcopenia Research (ICFSR)

Exhibit 99.1 Press release Biophytis presented Sarconeos (BIO101) as a possible treatment candidate for long COVID after hospitalization during the 13th annual International Conference on Frailty and Sarcopenia Research (ICFSR) Paris (France), Cambridge (Massachusetts, U.S.), March 27th, 2023, 08 am CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 21, 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 21, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis to Present Sarconeos’ (BIO101) Development as a Drug Candidate in Rare Neuromuscular Diseases at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Exhibit 99.1 Press release Biophytis to Present Sarconeos’ (BIO101) Development as a Drug Candidate in Rare Neuromuscular Diseases at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference Paris (France), Cambridge (Massachusetts, U.S.), March 20th, 2023, 08 am CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biot

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 17, 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 17, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program

EX-99.1 2 tm238333d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Press release Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program Paris (France), Cambridge (Massachusetts, U.S.), March 17th, 2023, 08 am CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused on the development of th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 9, 2023 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 9, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference

Exhibit 99.1 Press release Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference Paris (France), Cambridge (Massachusetts, U.S.), March 9th, 2023, 08 am CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the dege

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 2, 2023 Commission File Number: 001-38

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: March 2, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage 4

Biophytis announces the signature of a master service agreement with Intsel Chimos, a pharmaceutical company that will operate Sarconeos (BIO101) in France for the treatment of severe forms of COVID-19

Exhibit 99.1 Press release Biophytis announces the signature of a master service agreement with Intsel Chimos, a pharmaceutical company that will operate Sarconeos (BIO101) in France for the treatment of severe forms of COVID-19 · Biophytis and Intsel Chimos signed a master service agreement under which Intsel Chimos will be the operating pharmaceutical company/exploitant, partner and distributor

Biophytis initiates the regulatory process for an early access authorization in France from the French National Authority for Health (HAS) for the treatment with Sarconeos (BIO101) of severe forms of COVID-19

Exhibit 99.1 Press release Biophytis initiates the regulatory process for an early access authorization in France from the French National Authority for Health (HAS) for the treatment with Sarconeos (BIO101) of severe forms of COVID-19 · Biophytis to present the early access application in France at a pre-filing meeting in March with the HAS · Biophytis plans to file the application shortly after

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 28, 2023 Commission File Number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 28, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étag

Biophytis To Host A Combined General Shareholder’s Meeting On March 30, 2023

EX-99.1 2 tm237672d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Press release Biophytis To Host A Combined General Shareholder’s Meeting On March 30, 2023 · Delegation to the Board of Directors to reduce the nominal value · Regrouping of the company's shares · Renewal of Authorizations granted at the June 2022 AGM Paris (France), Cambridge (Massachusetts, USA), February 23, 2023, 8:00 a.m. CET - Biophyti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 23, 2023 Commission File Number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 23, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étag

Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19

Exhibit 99.1 Press release Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 · COVA study met primary end point with 44% significant reduction in the risk of respiratory failure or early death · Filing for Early Access Programs to Sarconeos (BIO101) is being initated while preparing for Marketing Authorisation in Europe and the USA Pa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 2, 2023 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: February 2, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 30, 2023 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 30, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University-BC 9, Bâtiment A 4ème étage

Biophytis publishes its financial results for the first half of 2022

Exhibit 99.1 Press release Biophytis publishes its financial results for the first half of 2022 · Cash and cash equivalents: €19.7m as of June 30, 2022 · Net loss down 8% at €12.4m for first half of 2022 Publication of restated financial results as of December 31st, 2021 Paris (France), Cambridge (Massachusetts, USA), January 31st 2023, 08am CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Pari

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 31, 2023 Commission File Number: 001

6-K 1 tm234994d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 31, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne Univer

Public limited company with a Board of Directors with share capital of 32,764,700.60 euros Registered office: 14 Avenue de l'Opéra – 75001 PARIS Paris Commercial Register (RCS) 492 002 225 HALF-YEAR FINANCIAL REPORT AS OF JUNE 30, 2022

Exhibit 99.1 Public limited company with a Board of Directors with share capital of 32,764,700.60 euros Registered office: 14 Avenue de l'Opéra – 75001 PARIS Paris Commercial Register (RCS) 492 002 225 HALF-YEAR FINANCIAL REPORT AS OF JUNE 30, 2022 Half-year financial report as of June 30, 2022 CONTENTS 1. Statement by the person responsible for the half-year financial report 4 1.1 Person responsi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 31, 2023 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 31, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage

Biophytis publishes its financial results for the first half of 2022

Exhibit 99.1 Press release Biophytis publishes its financial results for the first half of 2022 · Cash and cash equivalents: €19.7m as of June 30, 2022 · Net loss down 8% at €12.4m for first half of 2022 Publication of restated financial results as of December 31st, 2021 Paris (France), Cambridge (Massachusetts, USA), January 31st 2023, 08am CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Pari

Certificate of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Stanislas Veillet, certify that: 1. I have reviewed this annual report on Form 20-F/A of BIOPHYTIS S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) O

Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of BIOPHYTIS S.A. (the “Company”) on Form 20-F/A for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Evelyne Nguy

Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Philippe Rousseau, certify that: 1. I have reviewed this annual report on Form 20-F/A of BIOPHYTIS S.A.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact

Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of BIOPHYTIS S.A. (the “Company”) on Form 20-F/A for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Stanislas Ve

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 19, 2023 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 19, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage

Judgment of the Paris Court of Appeal of 17 January 2023 in the case between Biophytis and Negma Group Ltd The Paris Court of appeal confirms the judgement of the Paris Conmmercial Court of 16th of March 2021

Exhibit 99.1 Press release Judgment of the Paris Court of Appeal of 17 January 2023 in the case between Biophytis and Negma Group Ltd The Paris Court of appeal confirms the judgement of the Paris Conmmercial Court of 16th of March 2021 Paris (France), Cambridge (Massachusetts, U.S.), January 19th, 2023, 8am CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophy

Biophytis announces its participation in two major investor conferences in January, in the United States and in France: the JP Morgan Healthcare Conference and the Invest Securities Biomed Event

Exhibit 99.1 Press Release Biophytis announces its participation in two major investor conferences in January, in the United States and in France: the JP Morgan Healthcare Conference and the Invest Securities Biomed Event Paris (France), Cambridge (Massachusetts, United States), January 5, 2022 – 8 A.M – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”) a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 6, 2023 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: January 6, 2023 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant?s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University?BC 9, B?timent A 4?me ?tage

BIOPHYTIS ORGANISES A WEBCAST WITH KEY OPINION LEADERS (KOL) ON THE PHASE 2-3 COVA STUDY RESULTS OF SARCONEOS (BIO101) IN THE TREATMENT OF PNEUMONIA IN COVID-19 PATIENTS AT RISK OF RESPIRATORY FAILURE

Exhibit 99.1 Press release BIOPHYTIS ORGANISES A WEBCAST WITH KEY OPINION LEADERS (KOL) ON THE PHASE 2-3 COVA STUDY RESULTS OF SARCONEOS (BIO101) IN THE TREATMENT OF PNEUMONIA IN COVID-19 PATIENTS AT RISK OF RESPIRATORY FAILURE Following the positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in the treatment of pneumonia

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: December 1, 2022 Commission File Number: 001

6-K 1 tm2231754d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: December 1, 2022 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne Unive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 3, 2022 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 3, 2022 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant?s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University?BC 9, B?timent A 4?me ?tage

Biophytis reports positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in COVID-19

Exhibit 99.1 Press release Biophytis reports positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in COVID-19 ? A reduction in the risk of early death or respiratory failure at day 28 of 45% in the Intent-To-Treat (ITT) population and 53% in the Per Protocol (PP) population ? A reduction in the risk of death at day 90 of 43

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 2, 2022 Commission File Number: 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 2, 2022 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University—BC 9, Bâtiment A 4ème étage

Biophytis publishes its key financial figures as at 30 June 2022, announces a restatement of the financial statements published as of December 31st, 2021 and provides an update on the operational milestones

Exhibit 99.1 Press release Biophytis publishes its key financial figures as at 30 June 2022, announces a restatement of the financial statements published as of December 31st, 2021 and provides an update on the operational milestones Paris (France), Cambridge (Massachusetts, U.S.), October 31, 2022, 23pm CET ? Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the ?Company? or ?Biophytis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: October 26, 2022 Commission File Number: 001

6-K 1 tm2228961d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: October 26, 2022 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne Unive

Biophytis announces receipt of Nasdaq Notice

Exhibit 99.1 Press release Biophytis announces receipt of Nasdaq Notice Paris (France), Cambridge (Massachusetts, U.S.), October 26th, 2022, 8am CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including sever

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 19, 2022 Commission File Number: 0

6-K 1 tm2226151d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 19, 2022 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne Uni

Biophytis participates in H.C. Wainwright 24

Exhibit 99.1 Press release Biophytis participates in H.C. Wainwright 24th Annual Global Investment Conference Paris (France), Cambridge (Massachusetts, U.S.), September 15th, 2022, 08 am CET ? Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the ?Company? or ?Biophytis?), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative proces

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 13, 2022 Commission File Number: 0

6-K 1 tm2225767d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 13, 2022 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant’s name into English) Stanislas Veillet Biophytis S.A. Sorbonne Uni

The Paris Court of appeal rules in favour of Biophytis in the case against Negma Group Ltd

Exhibit 99.1 Press release The Paris Court of appeal rules in favour of Biophytis in the case against Negma Group Ltd ? On July 16th July 2021, the Paris Court had imposed on Biophytis a penalty payment of EUR 1,500,000 in favour of Negma Group Ltd, following a judgment of the Paris Commercial Court ? On September 8th 2022, the Paris Court of Appeal partially reversed the judgment of the Enforceme

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 7, 2022 Commission File Number: 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: September 7, 2022 Commission File Number: 001-38974 BIOPHYTIS S.A. (Translation of registrant?s name into English) Stanislas Veillet Biophytis S.A. Sorbonne University?BC 9, B?timent A 4?me ?tag